- Bluebird bio (NASDAQ:BLUE) announces two new appointments as part of the company’s ongoing preparation for commercial readiness. Susanna High has been named chief operating officer and Andrew Obenshain senior vice president and head of Europe.
- Prior to joining bluebird, Ms. High worked at Alnylam Pharmaceuticals responsible for company strategy, business planning and various other activities. She also worked at Millennium Pharmaceuticals (now Takeda Oncology).
- Previously, Mr. Obenshain served at Shire in Paris as General Manager of France and Benelux and at Sanofi Genzyme in management operations.